Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up

Table 3

Renal dysfunction.

	Randomization; population${}^1$		On-treatment; population${}^2$		Total
	MMF group${}^3$; $(n=48)$	Control group${}^4$; $(n=22)$	Group I${}^5$; $(n=56)$	Group II${}^6$; $(n=14)$	$(n=70)$
Number of events	12	6	15	3	18
Increased serum creatinine	7 (58.3%)	2 (33.3%)	8 (53.3%)	1 (33.3%)	9 (50%)
Acute rejection (biopsy proven)	0 (0%)	1 (16.7%)	1 (6.7%)	0 (0%)	1 (5.6%)
Chronic allograft nephropathy (biopsy proven)	3 (25%)	3 (50%)	4 (26.7%)	2 (66.7%)	6 (33.3%)
Recurrence of initial nephropathy	1 (8.3%)	0 (0%)	1 (6.7%)	0 (0%)	1 (5.6%)
Others	1 (8.3%)	0 (0%)	1 (6.7%)	0 (0%)	1 (5.6%)
Patients with at least one episode of renal dysfunction	8 (16.7%)	5 (22.7%)	10 (17.9%)	3 (21.4%)	13 (18.6%)

${}^1$ Patients randomized to receive either MMF or CsA treatment in the initial study phase.
${}^2$ Determined by the treatment patients received at the end of the post-trial phase (mycophenolic acid derivative or not).
${}^3$ Patients who received 2 g MMF per day and 50% of the initial CsA dose.
${}^4$ Patients who received the usual CsA dose.
${}^5$ Patients who received a treatment with a mycophenolic acid derivative at the end of the follow up phase.
${}^6$ Patients without a mycophenolic acid derivative at the end of the follow up phase.